Northeast Financial Consultants Inc acquired a new stake in Iqvia Holdings Inc (NYSE:IQV) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 4,466 shares of the medical research company’s stock, valued at approximately $642,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. C J Advisory Inc acquired a new position in shares of Iqvia in the first quarter valued at $27,000. Baystate Wealth Management LLC bought a new position in shares of Iqvia during the 1st quarter worth approximately $27,000. Parkside Financial Bank & Trust boosted its holdings in shares of Iqvia by 140.2% during the 1st quarter. Parkside Financial Bank & Trust now owns 209 shares of the medical research company’s stock worth $30,000 after buying an additional 122 shares in the last quarter. Berman Capital Advisors LLC bought a new position in shares of Iqvia during the 4th quarter worth approximately $46,000. Finally, ERTS Wealth Advisors LLC bought a new position in shares of Iqvia during the 4th quarter worth approximately $46,000. Institutional investors own 89.78% of the company’s stock.
In related news, Director Michael J. Evanisko sold 1,193 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $144.95, for a total value of $172,925.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kevin C. Knightly sold 46,080 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $138.06, for a total value of $6,361,804.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 143,273 shares of company stock worth $20,066,890. 6.00% of the stock is owned by company insiders.
Iqvia (NYSE:IQV) last issued its earnings results on Wednesday, May 1st. The medical research company reported $1.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.41 by $0.12. Iqvia had a return on equity of 15.08% and a net margin of 2.35%. The company had revenue of $2.68 billion for the quarter, compared to analysts’ expectations of $2.67 billion. During the same period last year, the business earned $1.34 EPS. Iqvia’s quarterly revenue was up 4.7% compared to the same quarter last year. On average, analysts expect that Iqvia Holdings Inc will post 5.88 EPS for the current year.
A number of equities analysts have issued reports on the company. Zacks Investment Research upgraded Iqvia from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. Leerink Swann assumed coverage on Iqvia in a report on Tuesday, May 28th. They set an “outperform” rating and a $136.38 price target on the stock. TheStreet cut Iqvia from a “b” rating to a “c+” rating in a report on Wednesday, May 1st. Wolfe Research assumed coverage on Iqvia in a report on Tuesday, April 2nd. They set a “market perform” rating on the stock. Finally, Svb Leerink assumed coverage on Iqvia in a report on Tuesday, May 28th. They set an “outperform” rating and a $160.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $147.02.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4370408/northeast-financial-consultants-inc-acquires-shares-of-4466-iqvia-holdings-inc-nyseiqv.html.
Iqvia Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading: How a Strangle Strategy is different from a Straddle Strategy
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.